Clinical TopicsOncologyOncology Resource CenterWeb Exclusives

FDA approves first targeted therapy for bladder cancer

On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following previous platinum-containing chemotherapy.

Read more at fda.gov.

Poll

Recent Posts